NR1H4 and Hepatic fibrosis: A further confounding factor in these apparently conflicting data might be the recently revealed beneficial effects of FXR agonists on gut barrier dysfunction, microbiota and bacterial translocation from the gut which in turn might result in reduced liver damage and a secondary decrease in hepatic fibrosis, especially in the CCl4-model36, 37, 38.